CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
GDTC Stock Chart & Stats
$1.39
-$0.41(-13.85%)
At close: 4:00 PM EST
$1.39
-$0.41(-13.85%)
Day’s Range― - ―
52-Week Range$0.73 - $3.68
Previous CloseN/A
Volume107.31K
Average Volume (3M)166.79K
Market Cap
$12.00M
Enterprise Value$10.04M
Total Cash (Recent Filing)$2.25M
Total Debt (Recent Filing)$385.05K
Price to Earnings (P/E)―
Beta0.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,828,435
10 Day Avg. Volume104,297
30 Day Avg. Volume166,789
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.98
Price to Sales (P/S)754.46
P/FCF Ratio-13.04
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue27.37
Enterprise Value/Gross Profit26.38
Enterprise Value/Ebitda-3.92
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform Expansion Via AcquisitionThe TCB-002 acquisition broadens CytoMed's non‑viral allogeneic gamma delta T‑cell platform, adds an asset with Phase I data and FDA orphan designation, and accelerates entry into China/India regulatory pathways, improving long‑term product and market optionality.
Clinical Partnerships And Trial FootprintThe Universiti Malaya MOU expands CytoMed's Southeast Asia clinical footprint and enables a multi‑site Phase I program, which supports regulatory filings, enhances patient recruitment and data robustness, and de‑risks clinical development for future licensing or partnerships.
Near-term Runway And Non-dilutive FundingReporting at least a year of resources plus a non‑dilutive investment for LongevityBank reduces immediate financing pressure, allowing focus on clinical milestones, strategic licensing and monetisation options with less near‑term dilution risk while development proceeds.
Bears Say
Revenue CollapseA dramatic decline in revenue signals weak commercialization or demand and undermines internal funding capacity for R&D and operations. Persistent low revenue increases reliance on external capital and raises execution and survival risk over the medium term.
Sustained Net Losses And Negative Free Cash FlowLarge net losses and a substantial FCF deficit indicate structural cash burn. Continued negative cash generation compels repeat fundraising or asset monetisation, which can dilute shareholders or delay programs if capital markets tighten, impairing long‑term execution.
Shrinking Balance Sheet BuffersDeclines in assets and equity reduce the company's financial resilience despite low debt. A weakened equity buffer limits capacity to absorb clinical or operational setbacks, constrains borrowing options and increases the likelihood of dilutive financings if cash burn persists.
CytoMed Therapeutics Limited News
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $0.73 and its highest was $3.68 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $12.00M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoMed Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 11,828,435 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Technical Analysis
Ownership Overview
20.35% Insiders
0.04% Mutual Funds
0.19% Other Institutional Investors
79.42% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---